Clinical trials: Epidermis
Port-Wine Stain
Measurement Skin Temperature During Pulsed Laser Exposure
Lasers are the treatment modality of choice for Port Wine Stain birthmarks.The epidermis is not totally spared due to partial absorption of energy therein by melanin that presents an optical barrier through which the light must…
- Trial name
- NCT00540917
- Testing
- cooling spray during laser treatment
- Where
- United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Breast Cancer, Metastatic Breast Cancer
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
The purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer
- Trial name
- SERIES (NCT06263543)
- Testing
- Sacituzumab govitecan
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- Reshma L. Mahtani, D.O.
Non-Small Cell Lung Cancer (NSCLC)
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
This study was designed to evaluate safety and antitumor activity of HER3-DXd in two parts: Dose Escalation and Dose Expansion. In Dose Escalation, HER3-DXd was evaluated in participants with metastatic or unresectable NSCLC with…
- Trial name
- NCT03260491
- Testing
- HER3-DXd (FL-DP), HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP)
- Where
- 37 sites in United States, Japan and 4 more
- Volunteers
- 312 people
- Sponsor
- Daiichi Sankyo
Breast Cancer
Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer
This research is being done because it is not yet known what dose of foretinib in combination with lapatinib can be given safely to patients with breast cancer, nor what type and severity of side effects will result from the…
- Trial name
- NCT01138384
- Testing
- Foretinib, Lapatinib
- Where
- 5 sites in Canada
- Volunteers
- 19 people
- Sponsor
- NCIC Clinical Trials Group
Advanced Breast Cancer
Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA)
The study aim is to perform a comprehensive and integrated characterization of mechanisms of primary and acquired resistance to Kadcyla in a prospective cohort of progressive/recurrent HER2-positive breast cancer patients.
- Trial name
- KATIA (NCT03829306)
- Where
- 10 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Spanish Breast Cancer Research Group
Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies
This phase I trial tests the safety, side effects, and best dose of genetically engineered cells called EGFRt/19-28z/IL-12 CAR T cells, and to see how they work in treating patients with hematologic malignancies that makes a…
- Conditions
- Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma
- Trial name
- NCT06343376
- Testing
- Biopsy, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Roswell Park Cancer Institute
Metastatic Pancreatic Carcinoma
A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
This is a phase I clinical trial examining the safety, feasibility, and toxicity of gemcitabine and erlotinib when given in combination with capecitabine in adult patients with locally advanced unresectable or metastatic…
- Trial name
- NCT00480584
- Testing
- gemcitabine, capecitabine, erlotinib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-small Cell Lung Cancer
Detection Cell Free DNA in Lung Cancer Patients
third generation of EGFR-TKIs is the newest target therapy for NSCLC. However, we did not known the specific mechanisms for those non-responders and patients grow resistance.Next generation sequencing is current the most…
- Trial name
- NCT02738593
- Where
- 2 sites in China
- Volunteers
- 124 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
The purpose of this study is to assess the safety of GDC-4198 alone and in combination with giredestrant and also the efficacy of GDC-4198 + giredestrant versus abemaciclib + giredestrant in participants with locally advanced or…
- Trial name
- MoonROSE (NCT07100106)
- Testing
- GDC-4198, Giredestrant, Abemaciclib
- Where
- 77 sites in United States, Australia and 8 more
- Volunteers
- 285 people
- Sponsor
- Genentech, Inc.
Cancer, Head and Neck Cancer
Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to estimate, with pre-specified precision, the difference in local-regional control (LRC) rate at 2 years in subjects receiving chemoradiotherapy (CRT) or panitumumab plus radiotherapy (PRT) as first…
- Conditions
- Cancer, Head and Neck Cancer, Oncology, Squamous Cell Carcinoma
- Trial name
- NCT00547157
- Testing
- Panitumumab, Cisplatin
- Volunteers
- 152 people
- Sponsor
- Amgen
Small Fiber Neuropathy
Pilot Study to Evaluate Changes in Intra-Epidermal Nerve Fiber Density (IENFD) in Patients With Small-Fiber Neuropathy
This prospective observational pilot study will evaluate structural, functional, and patient-reported outcomes in adults with small fiber neuropathy who receive Saluda Evoke ECAP-controlled spinal cord stimulation as part of…
- Trial name
- SAL SFN PILOT (NCT07704931)
- Testing
- Evoke SCS system
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- TriCity Research Center
Impaired Wound Healing, Venous Insufficiency of Leg
Clinical Trial to Evaluate Blister Graft Utilizing a Novel Harvesting Device for Treatment of Venous Leg Ulcers
Epidermal grafts are believed to promote healing by two mechanisms: graft take and the promotion of wound healing through the delivery of growth factors and the essential elements of tissue repair and wound healing.28 This study…
- Conditions
- Impaired Wound Healing, Venous Insufficiency of Leg, Diabetic Ulcers
- Trial name
- Cellutome (NCT02148302)
- Testing
- Harvesting Device (CelluTome©)
- Where
- 18 sites in United States
- Volunteers
- 123 people
- Sponsor
- SerenaGroup, Inc.
Is Targeted Therapy Increasing Survival Inoperable Nonsmall Cell Lung Cancer With Spinal Metastasis ?
Can Epidermal Growth Factor Receptor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis ?
Not significantly increased survival in T/T
- Trial name
- NCT02740894
- Testing
- Gefitinib
- Volunteers
- 100 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Solid Tumors
Study of IMC-11F8 in Patients With Tumors Who Have Not Responded to Standard Therapy
The purpose of this study is to determine if IMC-11F8 is safe for patients, and also to determine the best dose of IMC-11F8 to give to patients.
- Trial name
- NCT00801177
- Testing
- IMC-11F8, IMC-11F8 I.V.
- Where
- 2 sites in Netherlands
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Chronic Venous Insufficiency, CVI, Venous Malformations
Safety of the Sonablate HIFU System for the Ablation of Incompetent Veins of the Periphery
The goal of this clinical trial is to learn if the Sonablate High Intensity Focused Ultrasound device can be safely used to treat patients with Chronic Venous Incompetence (CVI) including those with venous malformations of the…
- Conditions
- Chronic Venous Insufficiency, CVI, Venous Malformations, Venous Leg Ulcers, Klippel-Trenaunay Syndrome
- Trial name
- HIFIVE (NCT06642051)
- Testing
- High Intensity focused ultrasound
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Sonablate
Carcinoma, Non-Small-Cell Lung
An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations
The purpose of this study is to provide expanded compassionate use access to mobocertinib, in participants with locally advanced or metastatic NSCLC harboring EGFR in-frame exon 20 insertion mutations and who have received at…
- Trial name
- NCT04535557
- Testing
- Mobocertinib 160 mg
- Sponsor
- Millennium Pharmaceuticals, Inc.
Metastatic Breast Cancer, Advanced Breast Cancer
Implementing Patients´ Competence in Oral Breast Cancer Therapy
The aim of the IMPACT - Implementing Patients' competence in oral breast cancer therapy - study is to evaluate the effectiveness of a standardized patient education and coaching and optional eMBSR for therapy management provided…
- Trial name
- IMPACT (NCT04030728)
- Volunteers
- 212 people
- Sponsor
- Onco Medical Consult GmbH
HER2-negative Breast Cancer, Stage II Breast Cancer
Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Conditions
- HER2-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT00679029
- Testing
- doxorubicin hydrochloride, cyclophosphamide, bevacizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Nebraska
Gastric Cancer
Her 2 Testing in Indian Patients With Gastric Cancer
Gastric cancer remains a major health issue and a leading cause of cancer death worldwide, although the prevalence and mortality of the disease have gradually decreased.
- Trial name
- NCT01814345
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Tata Memorial Hospital
Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer
Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer
Our study is aimed to evaluate the efficacy and safety of novel ADC named SHR-A1921 combined with Adebrelimab in endocrine therapy-failed HR (Hormone Receptor)-positive, HER2-negative advanced breast cancer.
- Conditions
- Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Trial name
- NCT06470672
- Testing
- SHR-A1921, Adebrelimab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.